Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PerkinElmer

This article was originally published in The Gray Sheet

Executive Summary

Neonatal screening kits produced at the firm's Norton, Ohio plant are subject to additional FDA testing and labeling requirements, per a Feb. 13 agreement with the agency allowing the resumption of production. The plant is slated to shut in approximately six months, with all manufacturing to be consolidated at a Turku, Finland site. U.S. marshals seized nearly $1 mil. in kits Feb. 4, due to a lack of response to QSR violations (1"The Gray Sheet" Feb. 9, 2004, p. 16)...

You may also be interested in...



PerkinElmer Neonatal IVD Seizure Attributed To Poor Documentation

Recent staff turnover at PerkinElmer's Norton, Ohio manufacturing site partly accounted for a failure to address QSR violations that prompted seizure of neonatal screening kits, according to the firm

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel